Expression of Fibroblast Growth Factor Receptor 3 in the Recurrence of Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
¸Í¿µÈñ, ÇãÈñÀç, Àº¼ö¿ë,
¼Ò¼Ó »ó¼¼Á¤º¸
¸Í¿µÈñ ( Maeng Young-Hee )
Á¦ÁÖ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø º´¸®Çб³½Ç
ÇãÈñÀç ( Huh Hee-Jae )
Á¦ÁÖ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ºñ´¢±â°úÇб³½Ç
Àº¼ö¿ë ( Eun Su-Yong )
Á¦ÁÖ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø »ý¸®Çб³½Ç
KMID : 0358320100510020094
Abstract
Purpose: The fibroblast growth factor receptor 3 (FGFR3) gene is known to be frequently mutated in noninvasive urothelial carcinomas of the bladder. In this study, we investigated the expression of FGFR3, Ki-67, and p53 in bladder cancers and the effects of expression on tumor recurrence.
Materials and Methods : Fifty-five cases of primary bladder cancer were examined by immunohistochemistry. The relationship of these markers with various clinicopathological factors, including recurrence, was assessed.
Results: Positivity for cytoplasmic FGFR3 (FGFR3-c) was associated with a lower cancer grade (p=0.022) and stage (p=0.011). Recurrence was more frequent in patients with a higher stage, negative FGFR3-c, and high Ki-67 expression. According to univariate analysis, predictors of recurrence-free survival included the following: age, stage, FGFR-c, Ki-67, and p53. However, none of these was independent from the other parameters in multivariate studies.
Conclusions: The immunohistochemical expression of FGFR3 is not only one of the characteristic features of lower-grade and lower-stage urothelial carcinoma but also a possible marker in predicting disease recurrence.
Å°¿öµå
Carcinoma; transitional cell;Fibroblast growth factor receptor 3;p53 genes;Recurrence
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸